RMD Open

is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.1
Citescore: 7.3
All metrics >>


Video Abstract

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Conclusions: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from weeks 16 to 52.

Find out more